Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Immunotherapy has achieved great outcome in clinic, and PD-1/PD-L1 immunotherapy is the most promising one. Due to the limitations of monoclonal antibodies, the discovery of small molecule drugs blocking PD-1/PD-L1 signaling has attracted great interest. In this issue, Wu et al summarized the advances in small molecule inhibitors targeting the PD-1/PD-L1.